Literature DB >> 31836907

Metachronous translocation renal cell carcinoma in a child with successfully treated medulloblastoma.

Mir Ibrahim Sajid1, Ayesha Saleem2, Muhammad Arshad2, Zehra Fadoo3, Nasir Ud Din4.   

Abstract

BACKGROUND: The most common primary CNS tumor in children is the medulloblastoma, which generally occurs in the posterior fossa and can spread through the CNS and spinal cord. Although the recurrence of renal cell carcinoma as a secondary tumor to neuroblastoma has been reported with successful anti-neoplastic treatment, the rare occurrence of a child who initially had medulloblastoma and then developed translocation renal cell carcinoma has never been reported before. CASE
PRESENTATION: We report the case of a 12-year-old boy who initially presented with complaints of vomiting and headache. An MRI head confirmed the presence of 4 × 4 × 3 cm lesion which was resected completely and histopathology report confirmed the diagnosis of medulloblastoma Grade IV. Four years later, the child came for a follow-up visit and during routine screening, a CT scan showed heterogeneous lesion arising from the lower pole calyx of right kidney. The patient was referred to pediatric surgery for right radical nephrectomy involving the right adrenal gland. The histopathology report was consistent with the diagnosis of translocation renal cell carcinoma.
CONCLUSION: Central nervous system (CNS) tumors remain the leading cause of death among pediatric neoplasms. We advise genetic testing of index cases and the establishment of an international tumor registry for a challenging disease.

Entities:  

Keywords:  Medulloblastoma; Nephrectomy; Renal Cell Carcinoma; Secondary Tumor

Mesh:

Year:  2019        PMID: 31836907     DOI: 10.1007/s00381-019-04447-y

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  8 in total

1.  Irradiation-Induced Secondary Tumors following Pediatric Central Nervous System Tumors: Experiences of a Single Institute in Taiwan (1975-2013).

Authors:  Chu-Yi Lee; Yi-Wei Chen; Yi-Yen Lee; Feng-Chi Chang; Hsin-Hung Chen; Shih-Chieh Lin; Donald Ming-Tak Ho; Ming-Chao Huang; Sang-Hue Yen; Tai-Tong Wong; Muh-Lii Liang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-04-24       Impact factor: 7.038

2.  Renal cell carcinoma with Xp 11.2 translocation as a second tumor in a long-term survivor of advanced neuroblastoma.

Authors:  Nawal Al-Mashaikhi; Janet Yang; Jefferson Terry; Ronald Barr
Journal:  Pediatr Hematol Oncol       Date:  2014-12-31       Impact factor: 1.969

3.  Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity.

Authors:  L J Medeiros; G Palmedo; H R Krigman; G Kovacs; J B Beckwith
Journal:  Am J Surg Pathol       Date:  1999-07       Impact factor: 6.394

4.  Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.

Authors:  Roger J Packer; Tianni Zhou; Emi Holmes; Gilbert Vezina; Amar Gajjar
Journal:  Neuro Oncol       Date:  2012-10-25       Impact factor: 12.300

Review 5.  Secondary oligodendroglioma after postoperative irradiation for medulloblastoma: a case report and review of the literature.

Authors:  Hong-Lin He; Ying-En Lee; Han-Jung Chen; Chao-Tien Hsu; Yu-Yi Huang; I-Wei Chang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 6.  Metachronous bilateral renal cell carcinoma with an interval of more than 10 years.

Authors:  Haruki Kume; Shinji Teramoto; Tadaichi Kitamura
Journal:  Int Urol Nephrol       Date:  2009-04-21       Impact factor: 2.370

Review 7.  Brain tumor stem cells.

Authors:  Ichiro Nakano; Harley I Kornblum
Journal:  Pediatr Res       Date:  2006-04       Impact factor: 3.756

8.  Two metachronous tumors induced by radiation therapy: case report and review of the literature.

Authors:  Takashi Sasayama; Masamitsu Nishihara; Kazuhiro Tanaka; Katsu Mizukawa; Kazumasa Ehara; Naoki Kanomata; Eiji Kohmura
Journal:  J Neurooncol       Date:  2008-03-29       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.